Microscopic view of bevacizumab molecules fighting cancer cells.

Bevacizumab: A Critical Review of its Use in Metastatic Colorectal Cancer Treatment

Lena Voss in Health & Wellness December 2025 • 4 min read.

"Exploring the benefits, limitations, and future directions of bevacizumab in the fight against advanced colorectal cancer."

Colorectal cancer (CRC) remains a significant global health challenge, ranking as one of the most commonly diagnosed cancers worldwide. For those diagnosed with metastatic colorectal cancer (mCRC), the prognosis has historically been grim. However, advancements in treatment strategies have led to notable improvements in survival rates.

One such advancement is the introduction of bevacizumab, a humanized monoclonal antibody that targets vascular endothelial growth factor (VEGF). VEGF plays a crucial role in angiogenesis, the formation of new blood vessels that tumors need to grow and spread. By blocking VEGF, bevacizumab disrupts the blood supply to tumors, inhibiting their growth and metastasis.

This article delves into a comprehensive review of bevacizumab's role in the treatment of metastatic colorectal cancer. We'll explore its mechanisms of action, clinical trial results, efficacy in different treatment settings, and potential biomarkers that may predict treatment response. Additionally, we will address the treatment-related toxicities associated with bevacizumab and strategies for mitigating them. The article aims to provide a balanced and insightful appraisal of bevacizumab's place in the ever-evolving landscape of mCRC therapy.

How Does Bevacizumab Work Against Colorectal Cancer?

Microscopic view of bevacizumab molecules fighting cancer cells.

Bevacizumab functions by neutralizing vascular endothelial growth factor A (VEGF-A), a protein that promotes angiogenesis. Angiogenesis is essential for tumor growth and metastasis because tumors need a blood supply to receive nutrients and oxygen. By inhibiting VEGF-A, bevacizumab prevents the formation of new blood vessels, effectively starving the tumor.

The process of angiogenesis is complex, involving various factors that stimulate endothelial cell proliferation and migration. VEGF is one of the most potent angiogenic factors, and its overexpression is often associated with increased risk of metastasis and poor prognosis in various cancers, including CRC.

Inhibiting Tumor Growth: By disrupting the blood supply, bevacizumab reduces the availability of nutrients and oxygen to the tumor cells.
Preventing Metastasis: Angiogenesis facilitates the spread of cancer cells to distant sites. Bevacizumab helps to prevent this process by blocking new blood vessel formation.
Enhancing Chemotherapy Efficacy: By normalizing tumor vasculature, bevacizumab can improve the delivery of chemotherapeutic agents to the tumor site.

While bevacizumab has shown promise in improving outcomes for mCRC patients, it is not without its limitations. Some patients do not respond to bevacizumab, and resistance can develop over time. Therefore, ongoing research focuses on identifying predictive biomarkers and developing strategies to overcome resistance.

The Future of Bevacizumab in Colorectal Cancer Treatment

Bevacizumab has undeniably transformed the treatment landscape for metastatic colorectal cancer. Its ability to target angiogenesis and disrupt tumor blood supply has led to improved survival rates and quality of life for many patients. As we look to the future, research efforts are focused on refining our understanding of bevacizumab's mechanisms of action, identifying predictive biomarkers, and developing strategies to overcome resistance. By continuing to innovate and personalize treatment approaches, we can further improve outcomes for individuals affected by this challenging disease.

About this Article -

This article was crafted using a human-AI hybrid and collaborative approach. AI assisted our team with initial drafting, research insights, identifying key questions, and image generation. Our human editors guided topic selection, defined the angle, structured the content, ensured factual accuracy and relevance, refined the tone, and conducted thorough editing to deliver helpful, high-quality information.See our About page for more information.

Everything You Need To Know

What is Bevacizumab and how does it work?

Bevacizumab is a humanized monoclonal antibody that targets vascular endothelial growth factor (VEGF). VEGF is a protein that promotes angiogenesis, which is the formation of new blood vessels. Tumors need these new blood vessels to grow and spread. By blocking VEGF, bevacizumab disrupts the blood supply to the tumor, effectively starving it and inhibiting its growth and metastasis. This process is crucial because angiogenesis is a key factor in tumor development and spread, making VEGF a prime target for cancer therapy. Bevacizumab's impact on angiogenesis affects not only tumor growth but also the delivery of chemotherapeutic agents to the tumor site.

Why is Bevacizumab used in the treatment of metastatic colorectal cancer?

Bevacizumab plays a significant role in treating metastatic colorectal cancer (mCRC) because it targets angiogenesis, a process essential for tumor growth and spread. By inhibiting vascular endothelial growth factor (VEGF), bevacizumab disrupts the formation of new blood vessels that tumors need to survive. This is important because it can slow down tumor growth, prevent metastasis, and even enhance the effectiveness of chemotherapy. However, not all patients respond to bevacizumab, and resistance can develop, highlighting the need for ongoing research to identify predictive biomarkers and strategies to overcome resistance.

What are the limitations and side effects associated with Bevacizumab?

While bevacizumab has shown promise in improving outcomes for mCRC patients, it is not without its limitations. Some patients do not respond to bevacizumab, and resistance can develop over time. The treatment can be associated with toxicities, such as hypertension, proteinuria, and increased risk of bleeding. Strategies for mitigating these side effects involve careful monitoring and management of blood pressure, kidney function, and other potential complications. Identifying predictive biomarkers is crucial to determine which patients are most likely to benefit from bevacizumab, while developing strategies to overcome resistance is essential for improving long-term outcomes.

What is the future of Bevacizumab in treating colorectal cancer?

Research efforts are focused on refining our understanding of bevacizumab's mechanisms of action, identifying predictive biomarkers, and developing strategies to overcome resistance. Identifying which patients are most likely to respond to bevacizumab is crucial for personalized treatment approaches. Strategies to overcome resistance may involve combining bevacizumab with other targeted therapies or chemotherapeutic agents. Further research is needed to fully realize the potential of bevacizumab and improve outcomes for individuals affected by metastatic colorectal cancer.

What is VEGF-A and how does Bevacizumab interact with it?

Bevacizumab works by neutralizing vascular endothelial growth factor A (VEGF-A), a protein that promotes angiogenesis. Angiogenesis is essential for tumor growth and metastasis because tumors need a blood supply to receive nutrients and oxygen. By inhibiting VEGF-A, bevacizumab prevents the formation of new blood vessels, effectively starving the tumor. By disrupting the blood supply, bevacizumab reduces the availability of nutrients and oxygen to the tumor cells, preventing metastasis and enhancing Chemotherapy efficacy.